Clinical trials: Etoposide, completed
Prostate Cancer
Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as mitoxantrone, etoposide, and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00627354
- Testing
- etoposide, mitoxantrone hydrochloride, prednisone
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Groupe D'Etude des Tumeurs Uro-Genitales
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in participants with relapsed/refractory diffuse large B-cell…
- Trial name
- ZUMA-7 (NCT03391466)
- Testing
- Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 359 people
- Sponsor
- Kite, A Gilead Company
Follicular Lymphoma
Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma
The purpose of this study is to determine the rate and duration of complete remission and molecular response in patients with relapsed/refractory follicular lymphoma, using a combined treatment with rituximab plus chemotherapy…
- Trial name
- NCT00366275
- Testing
- Immunochemotherapy, in vivo purging and autrotransplant
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Small Cell Lung Carcinoma
A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
This is a phase IIIB, single-arm, single-country, multicenter study of the safety and efficacy of atezolizumab in combination with carboplatin plus etoposide in patients who have ES-SCLC and are chemotherapy-naive for their…
- Trial name
- MAURIS (NCT04028050)
- Testing
- Atezolizumab, Carboplatin, Etoposide
- Where
- 25 sites in Italy
- Volunteers
- 155 people
- Sponsor
- Hoffmann-La Roche
Gastric Neuroendocrine Carcinoma (G-NEC), Postoperative Adjuvant Therapy for G-NEC
ML Decision Model for G-NEC Adjuvant Therapy
Gastric neuroendocrine carcinoma (G-NEC) is a rare and aggressive tumor originating from neuroendocrine cells in the stomach lining. It is characterized by a high propensity for recurrence and a generally poor prognosis.
- Conditions
- Gastric Neuroendocrine Carcinoma (G-NEC), Postoperative Adjuvant Therapy for G-NEC, Survival Outcomes, Machine Learning
- Trial name
- G-NEC (NCT06663852)
- Where
- China
- Volunteers
- 1,505 people
- Sponsor
- Chang-Ming Huang, Prof.
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of brentuximab vedotin that can be combined with ifosfamide, carboplatin, and etoposide in treating patients with Hodgkin lymphoma that has come back (relapsed) or is…
- Trial name
- BV-ICE (NCT02227199)
- Testing
- Brentuximab Vedotin, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Washington
AML With FLT3 Mutation
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
The purpose of this study was to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated AML who were refractory to or had relapse after first-line AML therapy as shown with…
- Trial name
- NCT03182244
- Testing
- Gilteritinib, Cytarabine, Mitoxantrone
- Where
- 49 sites in China, Malaysia and 3 more
- Volunteers
- 276 people
- Sponsor
- Astellas Pharma Inc
Brain and Central Nervous System Tumors
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003621
- Testing
- carmustine, cisplatin, etoposide
- Where
- 18 sites in United States
- Volunteers
- 29 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Multiple Myeloma and Plasma Cell Neoplasm
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003399
- Testing
- carmustine, cisplatin, cyclophosphamide
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Leukemia
Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002598
- Testing
- recombinant interferon alfa, sargramostim, cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
RATIONALE: Giving chemotherapy and radiation therapy to the entire body before an autologous peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00559104
- Testing
- carmustine, cyclophosphamide, etoposide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
Lymphoma
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00049595
- Testing
- bleomycin sulfate, filgrastim, pegfilgrastim
- Where
- 140 sites in Australia, Belgium and 11 more
- Volunteers
- 552 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Small Cell Lung Cancer (SCLC)
Pembrolizumab in Untreated Extensive SCLC
This is a multicenter, open-label, two armed, controlled, and randomized phase II trial investigating the activity of pembrolizumab in combination with standard chemotherapy in Extensive Disease (ED)-SCLC.
- Trial name
- REACTION (NCT02580994)
- Testing
- Pembrolizumab, cis/carboplatin and etoposide
- Where
- 18 sites in France, Italy and 1 more
- Volunteers
- 125 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Myeloma, Plasma-Cell, Lymphoma, Malignant
Multi-day Doses in Prevention of Nausea and Emesis
To assess emetic responses to multi-day doses of Palonosetron and Aprepitant and low dose dexamethasone +/- Prochlorperazine among patients with multiple myeloma and lymphoma undergoing autologous HSCT utilizing the Multinational…
- Trial name
- NCT00600353
- Testing
- Palonosetron, Aprepitant, Dexamethasone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Kansas Medical Center
Extragonadal Germ Cell Tumor, Teratoma
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extragonadal Germ Cell Tumor, Teratoma, Testicular Germ Cell Tumor
- Trial name
- NCT00104676
- Testing
- bleomycin sulfate, cisplatin, etoposide
- Where
- 24 sites in United States, France and 1 more
- Volunteers
- 263 people
- Sponsor
- UNICANCER
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002517
- Testing
- cytarabine, daunorubicin hydrochloride, dexamethasone
- Where
- 23 sites in Belgium, France and 1 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
The purpose of this study is to evaluate the efficacy and toxicity of Rituximab combined with ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) in the patients with diffuse large B cell lymphoma (DLBCL).
- Trial name
- NCT00568815
- Testing
- Rituximab combined with ESHAP
- Where
- China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Fudan University
Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
Background: The paradigm of combining therapeutic agents with non-overlapping toxicities for the treatment of malignancy produces clinical remissions and cures in a number of tumor types.
- Trial name
- NCT00069238
- Testing
- Alemtuzumab (Campath), EPOCH
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
AML
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication…
- Trial name
- NCT02039726
- Testing
- Quizartinib, Salvage Chemotherapy
- Where
- 131 sites in United States, Australia and 17 more
- Volunteers
- 367 people
- Sponsor
- Daiichi Sankyo
Lymphoblastic Leukemia, Acute, Childhood
A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)
This is an open-label study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine to assess this 5-drug treatment's safety and tolerability in pediatric patients with first relapse Acute Lymphoblastic…
- Trial name
- NCT00991133
- Testing
- Clofarabine incorporated into a 5-drug regimen
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Genzyme, a Sanofi Company